Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

Expert Opinion on Biological Therapy

Volumn 9, Issue 2, 2009, Pages 263-271

  Chu, Quincy Siu Chung ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aflibercept (VEGF trap); Angiogenesis; Cancer; Vascular endothelial growth factor (VEGF)

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; BAY 57 9352; BEVACIZUMAB; BIBF 1120; BMS 690514; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CT 322; CYC 116; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMC 1121 B; IMMUNOGLOBULIN F(AB) FRAGMENT; IRINOTECAN; MGCD 265; MOTESANIB; OSI 930; OXALIPLATIN; PACLITAXEL; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR; VINCRISTINE; XL 647; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A;

ABDOMINAL PAIN; ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; B CELL LYMPHOMA; BLEEDING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; COLORECTAL CARCINOMA; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONSTIPATION; CONTINUOUS INFUSION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DYSPHONIA; EPISTAXIS; ERYTHEMA; FATIGUE; FISTULA; GLIOBLASTOMA; HEADACHE; HEMOPTYSIS; HOARSENESS; HUMAN; HYPERTENSION; HYPOCALCEMIA; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MONOTHERAPY; MUCOSAL BLEEDING; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PAPULAR RASH; PERFORATION; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN TARGETING; PROTEINURIA; PROTHROMBIN TIME; RETINA BLOOD VESSEL OCCLUSION; REVIEW; SARCOMA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DEFECT; SOLID TUMOR; THROMBOEMBOLISM; THROMBOSIS; THYROID CANCER; TUMOR VASCULARIZATION; DRUG ANTAGONISM; NEOPLASM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; HUMANS; NEOPLASMS; RECOMBINANT FUSION PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 65349186800     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802666397     Document Type: Review

References (49)

1. Hyder SM, Stancel GM. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol Endocrinol 1999;13:806-811 (Pubitemid 30645298)
2. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1:27-31
3. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9(Suppl 1):2-10 (Pubitemid 38747842)
4. Veikkola T, Alitalo K. VEGFs, receptors and angiogenesis. Semin Cancer Biol 1999;9:211-220 (Pubitemid 29273837)
5. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008;8:880-887
6. List AF. Vascular endothelial growth factors signaling pathway as an emerging target for hematological malignancies. Oncologist 2001;6(Suppl 5):24-31 (Pubitemid 33054874)
7. Lee JC, Chow NH, Wang ST, et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748-753 (Pubitemid 30179746)
8. Kreuter M, Paulussen M, Boeckeler J, et al. Clinical significance of vascular endothelial growth factor-A expression in Ewing's sarcoma. Eur J Cancer 2006;42:1904-1911 (Pubitemid 44149095)
9. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med 2004;98:632-636 (Pubitemid 38949927)
10. Rosen LS. Clinical experiences with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(Suppl):36-44 (Pubitemid 34457339)
11. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against Her2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(Suppl 11):29-37 (Pubitemid 34816063)
12. Toi M, Matsumato T, Bando H. Vascular endothelial growth factor: its prognostic, predictive and therapeutic implications. Lancet Oncol 2001;2:667-673 (Pubitemid 33085812)
13. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225 (Pubitemid 32176299)
14. Hurwitz H, Fenrenbacher L, Novothy W, et al. Bevacizumab in combination with irinotecan/5-fluorouracil/leucovorin for the treatment of metastatic colorectal cancer: Results of a randomized Phase III trial. N Engl J Med 2004;350:2335-2342
15. Saltz LB, Clarke S, Diaz-Rubins E, et al. Bevacizumab in combination with oxaliplatin based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III trial. J Clin Oncol 2008;26:2013-2019
16. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Co-operative Oncology Group study E3200. J Clin Oncol 2007;25:1539-1544 (Pubitemid 46733080)
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel/Carboplatin alone or with Bevacizumab for non-small cell lung cancer. N Engl J Med 2006;355:2542-2550 (Pubitemid 44917502)
18. Miller K, Wang M, Gralow J, et al. Paclitaxel and bevacizumab versus Paclitaxel alone for metastatic breast cancer. N Eng J Med 2007;357:2666-2676
19. Ton NC, Parker GJ, Jackson A, et al. Phase I evaluation of CDP291, a PEGylated di Fab'conjugate that bind VEGFR2. Clin Cancer Res 2007;13:7113-7118
20. Camidge DR, Eckhardt SG, Diab S, et al. A Phase I dose-escalation study of weekly IMC-1121B, a fully humanized anti-VEGFR2 IgG1 monoclonal antibody in patients with advanced cancer [abstract 3032]. Proc Am Soc Clin Oncol Meeting 2006;24:128s
21. Krishnamurthis S, Lorusso PM, Goncalves PH, et al. Phase I study of weekly anti-vascular growth factor-1 monoclonal antibody IMC-18F1 in patients with advanced solid malignancies [abstract 14630]. Proc Am Soc Clin Oncol Meeting 2008;26;637s
22. Sweeney CJ, Chriorean EG, Mita MM, et al. Phase I study of CT-322, first Adnectin protein therapeutic and potent inhibitor of VEGFR-2, in patients (pts) with advanced solid tumors (ST) [abstract 3523]. Proc Am Soc Clin Oncol Meeting 2008;26:158s
23. Cherrington JM, Strawn LM, Shawver LK. New paradigns for the treatment of cancer; the role of anti-angiogenic agents, First edition. In: Klein G, Vande Woude GF, editors, Advances in Cancer Research. Academic Press, San Diego, CA; 2000;79. p. 1-38
24. Khun H, Hammerschmidt S, Wirtz H. Targeting tumor angiogenesis in lung cancer by suppression of vascular endothelial growth factor and its receptor - results from clinical trials and novel experimental approaches. Curr Med Chem 2007;14:3157-3165
25. Llovet JM, Ricci S, Mazzaferro, et al. Sorafenib in advanced hepatocellular carcinoma. N Eng J Med 2008;259:378-390
26. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338 (Pubitemid 44528723)
27. Motzer RJ, Hudson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic reanl cell carcinoma. N Eng J Med 2007;256:115-124 (Pubitemid 46089672)
28. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced renal-cell carcinoma. N Eng J Med 2007;356:125-134 (Pubitemid 46089673)
29. Holash J, Davis S, Papaopoulous N, et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398 (Pubitemid 34920936)
30. Cursiefen C, Chen L, Borges LP, et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004;113:1040-1050 (Pubitemid 38544126)
31. Riely GJ, Miller VA. Vascular endothelial growth factor Trap in non-small cell lung cancer. Clin Cancer Res 2007;13(15 Suppl):4623s-4627s (Pubitemid 47219736)
32. Bryne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003;9:5721-5728 (Pubitemid 37499496)
33. Huang J, Frischer JS, Serur A, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003;100:7785-7790 (Pubitemid 36760047)
34. Fukusawa M, Korc M. Vascular endothelial growth factor-Trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res 2004;10:3327-3332 (Pubitemid 38685437)
35. Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade of experimental Wilm's tumor and its persisting vasculature. Int J Oncol 2004;3:549-553
36. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007;131:463-475 (Pubitemid 350007692)
37. Hu L, Hofmann J, Holash J, et al. Vascular endothelial growth factor Trap combined with paclitaxel stilingly inhibits tumor and ascites, prolongs survival in a human ovarian cancer model. Clin Cancer Res 2005;11:6966-6971 (Pubitemid 41428755)
38. Rudge JS, Holash J, Hylton D, et al. VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007;104:18363-18370 (Pubitemid 350210713)
39. Wachsberger PR, Burd R, Cadi C, et al. VEGF Trap in combination with radiotherapy improves tumor control in U87 glioblastoma. Int J Radiat Oncol Biol 2007;67:1526-1537 (Pubitemid 46467151)
40. Dupont J, Schwartz LH, Koutcher J, et al. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies [abstract 3009]. Proc Am Soc Clin Oncol Meeting 2004;22:197s
41. Dupont J, Rothernberg ML, Spriggs DR, et al. Safety and pharmacokinetics of intravenous VEGF Trap in a phase I clinical trial of patients with advanced solid tumors [abstract 3029]. Proc Am Soc Clin Oncol Meeting 2005;23:199s
42. Massarelli E, Miller VA, Leighl NB, et al. Phase II study of he efficacy and safety of intravenous AVE0005 (VEGF Trap) given every 2 weeks in patients with platinum and erlotinib-resistant adenocarcinoma of lung [abstract 7627]. Proc Am Soc Clin Oncol 2007;25:416s
43. Tew WO, Colombo N, Ray-Coquard A, et al. VEGF Trap for patients with recurrent platinum-resistant epithelial ovarian cancer: Preliminary results of a randomized Phase II study [abstract 5508]. Proc Am Soc Clin Oncol 2007;25:276s
44. Tang P, Cohen SJ, Bjarnason GA, et al. Phase II of aflibercept in previously treated patients with metastatic colorectal cancer: A Princess Margaret Hospital Phase II Consortium trial [abstract 4027]. Proc Am Soc Clin Oncol 2008;26:184s
45. Hobday TJ, Rowland K, Dueck A, et al. N0537: A North Central Cancer Treatment Group (NCCTG) Phase II study of VEGF Trap in patients with metastatic breast cancer previously treated with anthracycline and/or taxanes abstract 164. Proc 2008 Breast Cancer Symposium 2008;167s
46. Meyer T, Robson T, Amirkhorsravi A, et al. Targeting angiogenesis in cancer: Bevacizumab-induced platelet activation as a possible cause for unexpected arterial thromboembolic events in clinical trials [abstract 1091]. Blood 2006;108:325a
47. Gerber HO, Wu Y, Yu L, et al. Mice expressing a human form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Am Sci USA 2007;104:3478-3483 (Pubitemid 46364184)
48. Schneider BP, Wang M, Radoich M, et al. Asdsociation of vascular growth factopr and vascular growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared to paclitaxel and Bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678
49. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal caner. J Clin Oncol 2008;26:1626-1634